Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis

Detalhes bibliográficos
Autor(a) principal: Wijnant, Gert Jan
Data de Publicação: 2018
Outros Autores: Van Bocxlaer, Katrien, Yardley, Vanessa, Harris, Andy, Alavijeh, Mo, Silva-Pedrosa, Rita, Antunes, Sandra, Mauricio, Isabel, Murdan, Sudaxshina, Croft, Simon L.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/116842
Resumo: Fungisome® (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe and effective therapeutic for the parasitic infection visceral leishmaniasis. Its potential in the treatment of cutaneous leishmaniasis (CL), a disfiguring form of the disease affecting the skin, is currently unknown. Here, we report the evaluation of the efficacy of F in the Leishmania major BALB/c murine model of CL, including a head-to-head comparison with the standard liposomal AmB formulation AmBisome® (A). Upon intravenous administration at dose levels of 5, 10 and 15 mg/kg of body weight (on days 0, 2, 4, 6 and 8), F showed clear signs of toxicity (at 15 mg/kg), while A did not. After complete treatment (day 10), the tolerated doses of 5 and 10 mg/kg F had significant antileishmanial activity (ED50 = 4.0 and 12.8 mg/kg for qPCR-based parasite load and lesion size, respectively), although less than that of A at identical doses (ED50 = 3.0 and 8.8 mg/kg). The efficacy of F was inferior compared to A because lower levels of the active agent AmB accumulated within the infected lesion. In conclusion, despite possibly being less safe and efficacious than A at equivalent doses, the moderate in vivo activity of F could indicate a role in the systemic pharmacotherapy of CL.
id RCAP_e11dd9db3eb681aad6d09cdaf8400ee2
oai_identifier_str oai:run.unl.pt:10362/116842
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasisAmphotericin BCutaneous leishmaniasisEfficacyLiposomePharmacokineticsParasitologyInfectious DiseasesPharmacology (medical)SDG 3 - Good Health and Well-beingFungisome® (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe and effective therapeutic for the parasitic infection visceral leishmaniasis. Its potential in the treatment of cutaneous leishmaniasis (CL), a disfiguring form of the disease affecting the skin, is currently unknown. Here, we report the evaluation of the efficacy of F in the Leishmania major BALB/c murine model of CL, including a head-to-head comparison with the standard liposomal AmB formulation AmBisome® (A). Upon intravenous administration at dose levels of 5, 10 and 15 mg/kg of body weight (on days 0, 2, 4, 6 and 8), F showed clear signs of toxicity (at 15 mg/kg), while A did not. After complete treatment (day 10), the tolerated doses of 5 and 10 mg/kg F had significant antileishmanial activity (ED50 = 4.0 and 12.8 mg/kg for qPCR-based parasite load and lesion size, respectively), although less than that of A at identical doses (ED50 = 3.0 and 8.8 mg/kg). The efficacy of F was inferior compared to A because lower levels of the active agent AmB accumulated within the infected lesion. In conclusion, despite possibly being less safe and efficacious than A at equivalent doses, the moderate in vivo activity of F could indicate a role in the systemic pharmacotherapy of CL.Global Health and Tropical Medicine (GHTM)Vector borne diseases and pathogens (VBD)Instituto de Higiene e Medicina Tropical (IHMT)RUNWijnant, Gert JanVan Bocxlaer, KatrienYardley, VanessaHarris, AndyAlavijeh, MoSilva-Pedrosa, RitaAntunes, SandraMauricio, IsabelMurdan, SudaxshinaCroft, Simon L.2021-05-03T22:37:03Z2018-08-012018-08-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article6application/pdfhttp://hdl.handle.net/10362/116842eng2211-3207PURE: 4053015https://doi.org/10.1016/j.ijpddr.2018.04.001info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:59:37Zoai:run.unl.pt:10362/116842Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:43:18.772657Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
title Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
spellingShingle Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
Wijnant, Gert Jan
Amphotericin B
Cutaneous leishmaniasis
Efficacy
Liposome
Pharmacokinetics
Parasitology
Infectious Diseases
Pharmacology (medical)
SDG 3 - Good Health and Well-being
title_short Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
title_full Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
title_fullStr Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
title_full_unstemmed Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
title_sort Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
author Wijnant, Gert Jan
author_facet Wijnant, Gert Jan
Van Bocxlaer, Katrien
Yardley, Vanessa
Harris, Andy
Alavijeh, Mo
Silva-Pedrosa, Rita
Antunes, Sandra
Mauricio, Isabel
Murdan, Sudaxshina
Croft, Simon L.
author_role author
author2 Van Bocxlaer, Katrien
Yardley, Vanessa
Harris, Andy
Alavijeh, Mo
Silva-Pedrosa, Rita
Antunes, Sandra
Mauricio, Isabel
Murdan, Sudaxshina
Croft, Simon L.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Global Health and Tropical Medicine (GHTM)
Vector borne diseases and pathogens (VBD)
Instituto de Higiene e Medicina Tropical (IHMT)
RUN
dc.contributor.author.fl_str_mv Wijnant, Gert Jan
Van Bocxlaer, Katrien
Yardley, Vanessa
Harris, Andy
Alavijeh, Mo
Silva-Pedrosa, Rita
Antunes, Sandra
Mauricio, Isabel
Murdan, Sudaxshina
Croft, Simon L.
dc.subject.por.fl_str_mv Amphotericin B
Cutaneous leishmaniasis
Efficacy
Liposome
Pharmacokinetics
Parasitology
Infectious Diseases
Pharmacology (medical)
SDG 3 - Good Health and Well-being
topic Amphotericin B
Cutaneous leishmaniasis
Efficacy
Liposome
Pharmacokinetics
Parasitology
Infectious Diseases
Pharmacology (medical)
SDG 3 - Good Health and Well-being
description Fungisome® (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe and effective therapeutic for the parasitic infection visceral leishmaniasis. Its potential in the treatment of cutaneous leishmaniasis (CL), a disfiguring form of the disease affecting the skin, is currently unknown. Here, we report the evaluation of the efficacy of F in the Leishmania major BALB/c murine model of CL, including a head-to-head comparison with the standard liposomal AmB formulation AmBisome® (A). Upon intravenous administration at dose levels of 5, 10 and 15 mg/kg of body weight (on days 0, 2, 4, 6 and 8), F showed clear signs of toxicity (at 15 mg/kg), while A did not. After complete treatment (day 10), the tolerated doses of 5 and 10 mg/kg F had significant antileishmanial activity (ED50 = 4.0 and 12.8 mg/kg for qPCR-based parasite load and lesion size, respectively), although less than that of A at identical doses (ED50 = 3.0 and 8.8 mg/kg). The efficacy of F was inferior compared to A because lower levels of the active agent AmB accumulated within the infected lesion. In conclusion, despite possibly being less safe and efficacious than A at equivalent doses, the moderate in vivo activity of F could indicate a role in the systemic pharmacotherapy of CL.
publishDate 2018
dc.date.none.fl_str_mv 2018-08-01
2018-08-01T00:00:00Z
2021-05-03T22:37:03Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/116842
url http://hdl.handle.net/10362/116842
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2211-3207
PURE: 4053015
https://doi.org/10.1016/j.ijpddr.2018.04.001
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 6
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138043236450304